Conservation systematics of the shield-backed trapdoor spiders of the nigrum-group (Mygalomorphae, idiopidae, idiosoma): Integrative taxonomy reveals a diverse and threatened fauna from south-western Australia [dataset]

Supplementary material from: Rix MG, Huey JA, Cooper SJB, Austin AD, Harvey MS (2018) Conservation systematics of the shield-backed trapdoor spiders of the nigrum-group (Mygalomorphae, Idiopidae, Idiosoma): integrative taxonomy reveals a diverse and threatened fauna from south-western Australia. ZooKeys 756: 1-121. https://doi.org/10.3897/zookeys.756.24397 Supplementary material 1: Atlas of morphology : Explanation note: Atlas of morphology for shield-backed trapdoor spiders of the Idiosoma nigrum-group, illustrating a representative selection of male specimens for each species, in five standard views. Supplementary material 2: GenBank data : Explanation note: Spreadsheet of specimens sequenced for the molecular analyses, with associated collection data and GenBank accession numbers. Supplementary material 3: COI dataset : Explanation note: Nexus file of the aligned COI dataset for 82 taxa. Supplementary material 4: FULL dataset : Explanation note: Nexus file of the aligned FULL dataset for 82 taxa. Supplementary material 5: COI p-distances : Explanation note: Spreadsheet with matrix of COI p-distances for 61 sequenced specimens of Idiosoma in the nigrum-group, along with a summary of mean inter- and intra-specific p-distances

Using Published HRTFS with Slab3D: Metric-Based Database Selection and Phenomena Observed

Presented at the 20th International Conference on Auditory Display (ICAD2014), June 22-25, 2014, New York, NY.In this paper, two publicly available head-related transfer function (HRTF) database collections are analyzed for use with the open-source slab3d rendering system. After conversion to the slab3d HRTF database format (SLH), a set of visualization tools and a five-step metric-based process are used to select a subset of databases for general use. The goal is to select a limited subset least likely to contain anomalous behavior or measurement error. The described set of open-source tools can be applied to any HRTF database converted to the slab3d format

Feasibility and safety of the airway bypass procedure for patients with emphysema

n/

Systematic Review of Multidisciplinary Chronic Pain Treatment Facilities

This study reviewed the published literature evaluating multidisciplinary chronic pain treatment facilities to provide an overview of their availability, caseload, wait times, and facility characteristics. A systematic literature review was conducted using PRISMA guidelines following a search of MEDLINE, PsycINFO, and CINAHL databases. Inclusion criteria stipulated that studies be original research, survey more than one pain treatment facility directly, and describe a range of available treatments. Fourteen articles satisfied inclusion criteria. Results showed little consistency in the research design used to describe pain treatment facilities. Availability of pain treatment facilities was scarce and the reported caseloads and wait times were generally high. A wide range of medical, physical, and psychological pain treatments were available. Most studies reported findings on the percentage of practitioners in different health care professions employed. Future studies should consider using more comprehensive search strategies to survey facilities, improving clarity on what is considered to be a pain treatment facility, and reporting on a consistent set of variables to provide a clear summary of the status of pain treatment facilities. This review highlights important information for policymakers on the scope, demand, and accessibility of pain treatment facilities.Samantha Fashler is supported by an Ontario Graduate Scholarship and a Canadian Institutes of Health Research (CIHR) Vanier Canada Graduate Scholarship. Lindsay Burns is supported by a Frederick Banting and Charles Best CIHR Doctoral Scholarship. Joel Katz is supported by a CIHR Canada Research Chair in Health Psychology. This project was conducted in collaboration with the Canadian Pain Coalition (CPC) as a part of the Report Card on Pain

Design of the exhale airway stents for emphysema (EASE) trial: an endoscopic procedure for reducing hyperinflation

<p>Abstract</p> <p>Background</p> <p>Airway Bypass is a catheter-based, bronchoscopic procedure in which new passageways are created that bypass the collapsed airways, enabling trapped air to exit the lungs. The Exhale Airway Stents for Emphysema (EASE) Trial was designed to investigate whether Exhale^®Drug-Eluting Stents, placed in new passageways in the lungs, can improve pulmonary function and reduce breathlessness in severely hyperinflated, homogeneous emphysema patients (NCT00391612).</p> <p>Methods/Design</p> <p>The multi-center, randomized, double-blind, sham-controlled trial design was posted on <url>http://www.clinicaltrials.gov</url> in October 2006. Because Bayesian statistics are used for the analysis, the proposed enrollment ranged from 225 up to 450 subjects at up to 45 institutions. Inclusion criteria are: high resolution CT scan with evidence of homogeneous emphysema, post-bronchodilator pulmonary function tests showing: a ratio of FEV₁/FVC < 70%, FEV₁≤50% of predicted or FEV₁< 1 liter, RV/TLC≥0.65 at screening, marked dyspnea score ≥2 on the modified Medical Research Council scale of 0-4, a smoking history of at least 20 pack years and stopped smoking for at least 8 weeks prior to enrollment. Following 16 to 20 supervised pulmonary rehabilitation sessions, subjects were randomized 2:1 to receive either a treatment (Exhale^®Drug-Eluting Stent) or a sham bronchoscopy. A responder analysis will evaluate the co-primary endpoints of an FVC improvement ≥12% of the patient baseline value and modified Medical Research Council dyspnea scale improvement (reduction) ≥1 point at the 6-month follow-up visit.</p> <p>Discussion</p> <p>If through the EASE Trial, Airway Bypass is shown to improve pulmonary function and reduce dyspnea while demonstrating an acceptable safety profile, then homogeneous patients will have a minimally invasive treatment option with meaningful clinical benefit.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: NCT00391612</p

AEGIS: New Evidence Linking Active Galactic Nuclei to the Quenching of Star Formation

Utilizing Chandra X-ray observations in the All-wavelength Extended Groth Strip International Survey (AEGIS) we identify 241 X-ray selected Active Galactic Nuclei (AGNs, L > 10^{42} ergs/s) and study the properties of their host galaxies in the range 0.4 < z < 1.4. By making use of infrared photometry from Palomar Observatory and BRI imaging from the Canada-France-Hawaii Telescope, we estimate AGN host galaxy stellar masses and show that both stellar mass and photometric redshift estimates (where necessary) are robust to the possible contamination from AGNs in our X-ray selected sample. Accounting for the photometric and X-ray sensitivity limits of the survey, we construct the stellar mass function of X-ray selected AGN host galaxies and find that their abundance decreases by a factor of ~2 since z~1, but remains roughly flat as a function of stellar mass. We compare the abundance of AGN hosts to the rate of star formation quenching observed in the total galaxy population. If the timescale for X-ray detectable AGN activity is roughly 0.5-1 Gyr--as suggested by black hole demographics and recent simulations--then we deduce that the inferred AGN "trigger" rate matches the star formation quenching rate, suggesting a link between these phenomena. However, given the large range of nuclear accretion rates we infer for the most massive and red hosts, X-ray selected AGNs may not be directly responsible for quenching star formation.Comment: 12 pages. Submitted to ApJ. Comments welcom

Effect of development of antibodies to hla and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome

AbstractObjective: A retrospective analysis was performed to examine the role of HLA antibodies and cytomegalovirus mismatch on the development of bronchiolitis obliterans syndrome and survival after lung transplantation. Methods: Of 339 consecutive lung transplantations performed over a 102-month interval, 301 patients survived at least 3 months. There was a minimum follow-up period of 13 months. Bronchiolitis obliterans syndrome was defined as a decline in forced expiratory volume in 1 second less than 80% of posttransplantation baseline and/or histologic presence of obliterative bronchiolitis and was defined as occurring “early” if documented within 3 years of transplantation. Variables analyzed included preoperative donor and recipient cytomegalovirus status and the development of antibodies to human leukocyte antigens after transplantation. Microcytotoxicity was used to determine the presence of antibodies to human leukocyte antigens. Variables were subjected to Kaplan-Meier analysis to determine their impact on freedom from bronchiolitis obliterans syndrome and survival. Results: The development of antibodies to human leukocyte antigens after transplantation correlated significantly with bronchiolitis obliterans syndrome (P = .02). The development of antibodies to human leukocyte antigens did not affect survival (P = .33) unless they were detected within 2 years of transplantation (P = .04). There was greater frequency of early bronchiolitis obliterans syndrome in cytomegalovirus seronegative patients who received allografts from seropositive donors compared with all other combinations (P = .02). There was also a trend toward worse survival of cytomegalovirus seronegative patients who received allografts from seropositive donors (P = .13). Conclusion: These data suggest that bronchiolitis obliterans syndrome is the result of an immune-mediated process in which HLA antibodies and cytomegalovirus may play a significant role. (J Thorac Cardiovasc Surg 1998;116:812-20

Inhibition of inducible nitric oxide synthase ameliorates rat lung allograft rejection

AbstractRecently, the inducible isoform of nitric oxide synthase has been shown to be an important immunomodulation molecule in allograft rejection. We have observed the production of nitric oxide during rejection and the effect of nitric oxide synthase inhibition on allograft rejection in a rat lung transplant model. Rat left lung allotransplants were performed in two strain combinations: brown Norway–to–F344 (major histocompatibility complex incompatible); and Lewis-to-F344 (minor loci incompatible) as severe and mild rejection models respectively. Syngeneic F344-to-F344 transplants were performed as a negative control. Nitric oxide production during rejection was determined by measuring the recipient's serum nitrite/nitrate levels as a stable end product of nitric oxide. The progression of rejection was evaluated radiographically and the grade of rejection was determined histologically. After operation, recipients of allotransplantation were randomly divided into two groups and received either aminoguanidine (200 mg/kg, intraperitoneal every 6 hours), a potent inducible nitric oxide synthase inhibitor, or normal saline treatment. The levels of serum nitrite and nitrate in recipients increased in the early phase of rejection in both allotransplant combinations. However, in the terminal phase of rejection, the serum nitrite/nitrate level decreased significantly compared with the peak level in the brown Norway–to–F344 recipients. The serum nitrite/nitrate levels in the syngeneic transplant recipients were normal during the entire observation period. In aminoguanidine-treated animals, serum nitrite/nitrate levels remained normal in both allograft combinations. Significant suppression of rejection in aminoguanidine-treated recipients was observed histologically and radiographically in comparison with untreated recipients in the brown Norway–to–F344 combination. In the Lewis-to-F344 combination, aminoguanidine treatment significantly ameliorated histologic rejection but did not affect radiologic appearance. We therefore conclude nitric oxide is produced during early allograft rejection and may prove to be a marker and mediator of early rejection. The inhibition of inducible nitric oxide synthase results in significant reduction in rat lung allograft rejection. (J THORAC CARDIOVASC SURG 1995;110:1449-60